JP2004531549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531549A5 JP2004531549A5 JP2002589008A JP2002589008A JP2004531549A5 JP 2004531549 A5 JP2004531549 A5 JP 2004531549A5 JP 2002589008 A JP2002589008 A JP 2002589008A JP 2002589008 A JP2002589008 A JP 2002589008A JP 2004531549 A5 JP2004531549 A5 JP 2004531549A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- methyl
- acceptable carrier
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 4
- -1 4-methyl-piperazino-methyl Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 108091008039 hormone receptors Proteins 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29142701P | 2001-05-16 | 2001-05-16 | |
| PCT/EP2002/005362 WO2002092091A1 (en) | 2001-05-16 | 2002-05-15 | Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009281667A Division JP2010059202A (ja) | 2001-05-16 | 2009-12-11 | Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531549A JP2004531549A (ja) | 2004-10-14 |
| JP2004531549A5 true JP2004531549A5 (https=) | 2009-08-13 |
| JP4477303B2 JP4477303B2 (ja) | 2010-06-09 |
Family
ID=23120246
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589008A Expired - Lifetime JP4477303B2 (ja) | 2001-05-16 | 2002-05-15 | Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
| JP2009281667A Ceased JP2010059202A (ja) | 2001-05-16 | 2009-12-11 | Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009281667A Ceased JP2010059202A (ja) | 2001-05-16 | 2009-12-11 | Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20040167134A1 (https=) |
| EP (2) | EP2253319A1 (https=) |
| JP (2) | JP4477303B2 (https=) |
| KR (2) | KR20080091866A (https=) |
| CN (1) | CN1700917B (https=) |
| AT (1) | ATE359790T1 (https=) |
| AU (1) | AU2002342335B2 (https=) |
| BR (1) | BR0209647A (https=) |
| CA (1) | CA2444867C (https=) |
| CO (1) | CO5540315A2 (https=) |
| CZ (1) | CZ299756B6 (https=) |
| DE (1) | DE60219617T2 (https=) |
| DK (1) | DK1392313T3 (https=) |
| EC (1) | ECSP034823A (https=) |
| ES (1) | ES2283570T3 (https=) |
| HU (1) | HUP0400038A3 (https=) |
| IL (1) | IL158274A0 (https=) |
| MX (1) | MXPA03010401A (https=) |
| NO (2) | NO325453B1 (https=) |
| NZ (1) | NZ529145A (https=) |
| PL (2) | PL368068A1 (https=) |
| PT (1) | PT1392313E (https=) |
| RU (1) | RU2318517C2 (https=) |
| SI (1) | SI1392313T1 (https=) |
| SK (1) | SK14042003A3 (https=) |
| WO (1) | WO2002092091A1 (https=) |
| ZA (1) | ZA200307665B (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815241B2 (en) | 2005-11-07 | 2014-08-26 | Eisai R&D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| AU2007201056B2 (en) * | 2002-01-28 | 2010-06-10 | Hyks-Instituutti Oy | Treatment of rheumatoid arthritis using imatinib |
| GB0201882D0 (en) * | 2002-01-28 | 2002-03-13 | Novartis Ag | Organic compounds |
| GB0202874D0 (en) * | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| ATE508747T1 (de) | 2003-03-10 | 2011-05-15 | Eisai R&D Man Co Ltd | C-kit kinase-hemmer |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| GB0311971D0 (en) * | 2003-05-23 | 2003-06-25 | Novartis Ag | Organic compounds |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| RU2420279C3 (ru) * | 2005-08-03 | 2017-03-14 | Новартис Аг | Применение ингибиторов hdac для лечения миеломы |
| EP1942937A1 (en) * | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| CN1899616A (zh) * | 2006-07-20 | 2007-01-24 | 中国人民解放军军事医学科学院生物工程研究所 | 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途 |
| WO2008026748A1 (en) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| CA2676796C (en) | 2007-01-29 | 2016-02-23 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
| KR101506062B1 (ko) * | 2008-01-29 | 2015-03-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 저해 물질과 탁산의 병용 |
| BRPI0914790A2 (pt) * | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| DE3776880D1 (de) | 1986-11-21 | 1992-04-02 | Ciba Geigy Ag | Neue substituierte alkandiphosphonsaeuren. |
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
| US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0888458A4 (en) * | 1996-02-20 | 2004-05-06 | Sloan Kettering Institutefor C | COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| WO1997039135A1 (en) * | 1996-04-17 | 1997-10-23 | Board Of Regents, The University Of Texas System | Enhanced expression of transgenes |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US20010051628A1 (en) * | 1998-05-04 | 2001-12-13 | H.-J. Su Huang | Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
| US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| CN1660840A (zh) | 1999-03-30 | 2005-08-31 | 诺瓦提斯公司 | 治疗炎性疾病的酞嗪衍生物 |
| GB9907908D0 (en) * | 1999-04-07 | 1999-06-02 | Bataille Regis | Organic compounds |
| GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| EP1214092A2 (en) * | 1999-09-15 | 2002-06-19 | Wyeth | Method of potentiating chemotherapy and treating solid tumors |
| AU775373B2 (en) * | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| AU778042B2 (en) * | 1999-10-19 | 2004-11-11 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| WO2002000024A1 (en) * | 2000-06-30 | 2002-01-03 | The Regents Of The University Of California | New strategy for leukemia therapy |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| WO2002030429A1 (en) * | 2000-10-06 | 2002-04-18 | Biomedicines, Inc. | Combination therapy for the treatment of estrogen-sensitive disease |
| CN1276754C (zh) * | 2000-10-27 | 2006-09-27 | 诺瓦提斯公司 | 胃肠基质肿瘤的治疗 |
| RU2313345C2 (ru) * | 2001-02-27 | 2007-12-27 | Новартис Аг | Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона |
| US20060154936A1 (en) * | 2002-10-25 | 2006-07-13 | Lasky Joseph A | Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| US8168621B2 (en) * | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
| TW200740776A (en) * | 2006-02-06 | 2007-11-01 | Osi Pharm Inc | N-phenylbenzotriazolyl c-kit inhibitors |
| EP2285976A4 (en) * | 2008-05-15 | 2011-10-26 | Univ Southern California | ERCC-1 EXPRESSION AS A PROGNOSIS FOR CHEMOTHERAPEUTIC RESULTS |
-
2002
- 2002-05-15 CA CA2444867A patent/CA2444867C/en not_active Expired - Fee Related
- 2002-05-15 MX MXPA03010401A patent/MXPA03010401A/es active IP Right Grant
- 2002-05-15 ES ES02743024T patent/ES2283570T3/es not_active Expired - Lifetime
- 2002-05-15 PT PT02743024T patent/PT1392313E/pt unknown
- 2002-05-15 AT AT02743024T patent/ATE359790T1/de not_active IP Right Cessation
- 2002-05-15 NZ NZ529145A patent/NZ529145A/en unknown
- 2002-05-15 EP EP10173158A patent/EP2253319A1/en not_active Withdrawn
- 2002-05-15 DE DE60219617T patent/DE60219617T2/de not_active Expired - Fee Related
- 2002-05-15 EP EP02743024A patent/EP1392313B1/en not_active Expired - Lifetime
- 2002-05-15 US US10/476,817 patent/US20040167134A1/en not_active Abandoned
- 2002-05-15 DK DK02743024T patent/DK1392313T3/da active
- 2002-05-15 CN CN028093623A patent/CN1700917B/zh not_active Expired - Fee Related
- 2002-05-15 BR BR0209647-1A patent/BR0209647A/pt not_active IP Right Cessation
- 2002-05-15 CZ CZ20033098A patent/CZ299756B6/cs not_active IP Right Cessation
- 2002-05-15 PL PL02368068A patent/PL368068A1/xx unknown
- 2002-05-15 WO PCT/EP2002/005362 patent/WO2002092091A1/en not_active Ceased
- 2002-05-15 SK SK1404-2003A patent/SK14042003A3/sk not_active Application Discontinuation
- 2002-05-15 RU RU2003135786/14A patent/RU2318517C2/ru not_active IP Right Cessation
- 2002-05-15 PL PL392652A patent/PL392652A1/pl unknown
- 2002-05-15 AU AU2002342335A patent/AU2002342335B2/en not_active Ceased
- 2002-05-15 KR KR1020087023228A patent/KR20080091866A/ko not_active Ceased
- 2002-05-15 IL IL15827402A patent/IL158274A0/xx unknown
- 2002-05-15 SI SI200230560T patent/SI1392313T1/sl unknown
- 2002-05-15 JP JP2002589008A patent/JP4477303B2/ja not_active Expired - Lifetime
- 2002-05-15 KR KR10-2003-7014844A patent/KR20030094415A/ko not_active Abandoned
- 2002-05-15 HU HU0400038A patent/HUP0400038A3/hu unknown
-
2003
- 2003-10-01 ZA ZA200307665A patent/ZA200307665B/en unknown
- 2003-10-21 NO NO20034713A patent/NO325453B1/no not_active IP Right Cessation
- 2003-10-29 EC EC2003004823A patent/ECSP034823A/es unknown
- 2003-11-06 CO CO03098325A patent/CO5540315A2/es not_active Application Discontinuation
-
2007
- 2007-12-07 NO NO20076323A patent/NO20076323L/no not_active Application Discontinuation
-
2009
- 2009-04-14 US US12/423,079 patent/US20090202541A1/en not_active Abandoned
- 2009-12-11 JP JP2009281667A patent/JP2010059202A/ja not_active Ceased
-
2012
- 2012-07-17 US US13/551,079 patent/US20120283206A1/en not_active Abandoned
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969344B2 (en) | 2005-08-02 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US8815241B2 (en) | 2005-11-07 | 2014-08-26 | Eisai R&D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| US9006256B2 (en) | 2006-05-18 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004531549A5 (https=) | ||
| DE69713890T2 (de) | Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht | |
| JP2005502643A5 (https=) | ||
| MXPA04010496A (es) | Tableta con alta carga de farmaco. | |
| CA2440111A1 (en) | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative | |
| JP2002520274A (ja) | バルサルタンとカルシウムチャンネルブロッカーの抗高血圧組合わせ | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| JP2008534552A (ja) | 血栓症治療用の新規な医薬組成物 | |
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| TW202027749A (zh) | 急性骨髓性白血病用抗腫瘤劑 | |
| US7879868B2 (en) | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents | |
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| KR20040078123A (ko) | 에포틸론 및 대사길항물질을 포함하는 조합물 | |
| JP4854198B2 (ja) | 慢性リンパ性白血病の処置のためのナイトロジェンマスタードアナログとイマチニブの組み合わせ剤 | |
| HU222888B1 (hu) | Anilid vegyületek alkalmazása I típusú allergiás betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására | |
| JPH11508566A (ja) | リファブチンを含む抗細菌相乗性組成物 | |
| WO1993019758A1 (en) | Compositions and methods for treating benign prostatic hypertrophy | |
| DE60214533T2 (de) | Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen | |
| CN1111406C (zh) | 含咪唑衍生物的抗hiv组合物 | |
| WO2021048419A1 (en) | Combination therapies comprising trametinib for the treatment of cholangiocarcinoma | |
| JPH0840903A (ja) | 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物 | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| JP3254712B2 (ja) | 医薬組成物 | |
| EP1391203A1 (en) | Antitumor agents |